Abstract
ABH antigenicity and unspecific immune response were evaluated in 31 patients with superficial transitional cell carcinoma. 26% of these patients showed a reduced dinitrochlorobenzene (DNCB) reaction. There was no significant difference in the monocyte chemotaxis of patients with benign urological diseases and patients with superficial bladder cancer. However, a significant difference exists ...
Abstract
ABH antigenicity and unspecific immune response were evaluated in 31 patients with superficial transitional cell carcinoma. 26% of these patients showed a reduced dinitrochlorobenzene (DNCB) reaction. There was no significant difference in the monocyte chemotaxis of patients with benign urological diseases and patients with superficial bladder cancer. However, a significant difference exists versus patients with deeply infiltrating carcinomas. 20 patients revealed a loss of ABH antigens on the initial tumor. During the follow-up of at least 1 year, patients with negative DNCB skin test, reduced monocyte chemotaxis and negative specific red cell adherence test demonstrated a high rate of recurrent tumors and in 1 of 7 a progressive tumor developed.
Altmetric